Press Releases

Year

Immatics Announces Third Quarter 2021 Financial Results and Provides Business Update

Interim data update at SITC for ongoing ACTe ngine ® IMA203 trial targeting PRAME demonstrated clinical responses a cross multiple solid tumor types during dose escalation phase Immatics to i nitiate three expansion cohorts for IMA203 targeting PRAME : monotherapy, combination with checkpoint

Nov 16, 2021

PDF Version

Immatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine® IMA203 Phase 1a Trial Targeting PRAME

Company to host conference call on Tuesday, November 9 at 8:30 am EST Dose escalation for cell therapy candidate ACTengine® IMA203 ongoing; dose level 3 completed at doses below 1 billion transduced cells Objective responses (RECIST 1.1) observed in 8/16 patients (50%) across multiple solid

Nov 09, 2021

PDF Version

Immatics to Present Update on Lead ACTengine® Program IMA203 Targeting PRAME at the Society for Immunotherapy of Cancer’s 36th Annual Meeting

Houston, Texas and Tuebingen, Germany, November 1, 2021 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that the company will provide an update on its

Nov 01, 2021

Immatics Announces Second Quarter 2021 Financial Results and Provides Business Update

ACTengine ® patient recruitment remains on track ; a s of en d of July, a total of 2 7 patients have been treated with IMA201, IMA202 or IMA203 across different cancer indications TCR Bispecifics pipeline advancing with progress towards clinical trial initiation of IMA401 and preclinical

Aug 10, 2021

PDF Version

Immatics Announces Changes to its Board of Directors

Tuebingen , Germany and Houston, Texas , May 26 , 2021 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced changes to its Board of Directors.

May 26, 2021

PDF Version

Immatics Announces First Quarter 2021 Financial Results and Business Update

Data update for ongoing ACTengine® IMA200 clinical trial series demonstrate d first anti-tumor activity in heavily pre-treated solid cancer patients during early phases of dose escalation Next ACTengine® data update for dose level s 2 and 3 on track for H2 2021 P reclinical proof-of-concept for

May 18, 2021

PDF Version

Immatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA402 Targeting PRAME

Immatics ’ second TCR Bispecific s program IMA402 demonstrate s t umor cell killing in vitro and complete regression s of established tumor s in a n in vivo tumor model IMA402 targets a n Immatics - validated peptide derived from PRAME, one of the most frequent ly expressed intracellular cancer

May 11, 2021

PDF Version

Immatics Announces Full Year 2020 Financial Results and Corporate Update

Phase 1a data update from clinical ACTengine ® programs demonstrated first anti-tumor activity at early phases of dose escalation in heavily pre-treated solid cancer patients Enrollment across clinical ACTengine ® IMA200 trial series continues to scale up Cash and cash equivalents as well as other

Mar 30, 2021

PDF Version

Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs

Company to host conference call on Wednesday, March 17 at 8:30 am EST · First anti-tumor activity observed in heavily pre-treated solid cancer patients during early phases of dose escalation · Tumor shrinkage observed in 8 out of 10 patients including one partial response consistent with robust

Mar 17, 2021

PDF Version

Press Releases

Press Contact

Press Releases